Javascript must be enabled to continue!
The roles of glycolysis in osteosarcoma
View through CrossRef
Metabolic reprogramming is of great significance in the progression of various cancers and is critical for cancer progression, diagnosis, and treatment. Cellular metabolic pathways mainly include glycolysis, fat metabolism, glutamine decomposition, and oxidative phosphorylation. In cancer cells, reprogramming metabolic pathways is used to meet the massive energy requirement for tumorigenesis and development. Metabolisms are also altered in malignant osteosarcoma (OS) cells. Among reprogrammed metabolisms, alterations in aerobic glycolysis are key to the massive biosynthesis and energy demands of OS cells to sustain their growth and metastasis. Numerous studies have demonstrated that compared to normal cells, glycolysis in OS cells under aerobic conditions is substantially enhanced to promote malignant behaviors such as proliferation, invasion, metastasis, and drug resistance of OS. Glycolysis in OS is closely related to various oncogenes and tumor suppressor genes, and numerous signaling pathways have been reported to be involved in the regulation of glycolysis. In recent years, a vast number of inhibitors and natural products have been discovered to inhibit OS progression by targeting glycolysis-related proteins. These potential inhibitors and natural products may be ideal candidates for the treatment of osteosarcoma following hundreds of preclinical and clinical trials. In this article, we explore key pathways, glycolysis enzymes, non-coding RNAs, inhibitors, and natural products regulating aerobic glycolysis in OS cells to gain a deeper understanding of the relationship between glycolysis and the progression of OS and discover novel therapeutic approaches targeting glycolytic metabolism in OS.
Title: The roles of glycolysis in osteosarcoma
Description:
Metabolic reprogramming is of great significance in the progression of various cancers and is critical for cancer progression, diagnosis, and treatment.
Cellular metabolic pathways mainly include glycolysis, fat metabolism, glutamine decomposition, and oxidative phosphorylation.
In cancer cells, reprogramming metabolic pathways is used to meet the massive energy requirement for tumorigenesis and development.
Metabolisms are also altered in malignant osteosarcoma (OS) cells.
Among reprogrammed metabolisms, alterations in aerobic glycolysis are key to the massive biosynthesis and energy demands of OS cells to sustain their growth and metastasis.
Numerous studies have demonstrated that compared to normal cells, glycolysis in OS cells under aerobic conditions is substantially enhanced to promote malignant behaviors such as proliferation, invasion, metastasis, and drug resistance of OS.
Glycolysis in OS is closely related to various oncogenes and tumor suppressor genes, and numerous signaling pathways have been reported to be involved in the regulation of glycolysis.
In recent years, a vast number of inhibitors and natural products have been discovered to inhibit OS progression by targeting glycolysis-related proteins.
These potential inhibitors and natural products may be ideal candidates for the treatment of osteosarcoma following hundreds of preclinical and clinical trials.
In this article, we explore key pathways, glycolysis enzymes, non-coding RNAs, inhibitors, and natural products regulating aerobic glycolysis in OS cells to gain a deeper understanding of the relationship between glycolysis and the progression of OS and discover novel therapeutic approaches targeting glycolytic metabolism in OS.
Related Results
Abstract 1261: Targeting IL-11Rα inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model
Abstract 1261: Targeting IL-11Rα inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model
Abstract
Osteosarcoma is the most common primary tumor of bones. In the past three decades treatment paradigms and survival rates have not improved. While osteosarco...
Abstract A18: Comprehensive identification of bone cancer driver genes by using Li-Fraumeni syndrome iPSCs
Abstract A18: Comprehensive identification of bone cancer driver genes by using Li-Fraumeni syndrome iPSCs
Abstract
Osteosarcoma, the primary malignant tumor of bone, is the most frequent primary non-hematologic malignancy in children and adolescents. Despite the advances...
Silencing FUT4 Inhibits the Progression of Osteosarcoma through Activation of
FOXO1
Silencing FUT4 Inhibits the Progression of Osteosarcoma through Activation of
FOXO1
Background:
It has been reported that inhibition of Fucosyltransferase4 (FUT4) to activate Forkhead
box O1 (FOXO1) can lead to apoptosis of cancer cells, however, the mechanism in ...
Periosteal osteosarcoma of the clavicle
Periosteal osteosarcoma of the clavicle
ABSTRACT
Introduction:
Osteosarcomas arising from the bone cortical surface can be subdivided into parosteal, periosteal,...
Comprehensive Analysis of Aerobic Exercise-Related Genes Identifies CDCA4 That Promotes the Progression of Osteosarcoma
Comprehensive Analysis of Aerobic Exercise-Related Genes Identifies CDCA4 That Promotes the Progression of Osteosarcoma
BackgroundExercise has a positive impact on patients with osteosarcoma, improving function, reducing disability, maintaining independence and quality of life. Exercise may also dir...
Identification and validation of the important role of YAP in the development and progression of Osteosarcoma
Identification and validation of the important role of YAP in the development and progression of Osteosarcoma
Abstract
Aim
This study aims to explore the molecular mechanisms of osteosarcoma by integrating multi-omics data to identify key genes and pathways, with a focus on the Hi...
Osteosarcoma transcriptome data exploration reveals STC2 as a novel risk indicator in disease progression
Osteosarcoma transcriptome data exploration reveals STC2 as a novel risk indicator in disease progression
Abstract
Background
Osteosarcoma has been the most common primary bone malignant tumor in children and adolescents. Despite the considerable improvement in the und...
Osteosarcoma transcriptome data exploration reveals STC2 as a novel risk indicator in disease progression
Osteosarcoma transcriptome data exploration reveals STC2 as a novel risk indicator in disease progression
Abstract
Background
Osteosarcoma has been the most common primary bone malignant tumor in children and adolescents. Despite the...

